From Cagrilintide + Semaglutide to Zenagamtide: How GLP-1 and Amylin Signaling Are Reshaping Metabolic Research Architecture
CagriSema and zenagamtide represent two of the most interesting examples of how modern metabolic peptide research is moving beyond the era of the single target.
GLP-1 receptor science transformed modern metabolic research, but the newest development programs are asking a more ambitious question:
What happens when multiple metabolic signaling pathways are engineered into the same research strategy?
Two programs have moved directly into the center of that discussion: CagriSema and zenagamtide, formerly known as amycretin.
Both investigate the intersection of GLP-1 and amylin receptor biology, but their molecular architectures are fundamentally different.
CagriSema combines two pharmacological components—cagrilintide and semaglutide.
Zenagamtide takes a more integrated approach: it is being developed as one peptide molecule with activity at both GLP-1 and amylin receptors.
For researchers following the evolution from single-pathway compounds toward increasingly sophisticated metabolic systems, the distinction between CagriSema and zenagamtide is important.
It represents two different answers to the same larger question:
How can multiple biological signals be brought together within one research architecture?
That question is becoming one of the defining themes of next-generation metabolic science.
1. CagriSema and Zenagamtide Move Beyond the Single-Target Era
The biology of metabolism is not controlled by one receptor.
It involves interconnected signaling across the gastrointestinal system, pancreas, central nervous system, adipose tissue, liver, skeletal muscle and multiple endocrine pathways.
That complexity is driving a fundamental change in drug-development strategy.
Instead of asking only:
“How strongly can one receptor be activated?”
researchers are increasingly asking:
“Which signaling pathways complement each other, and how can those pathways be investigated together?”
We have already explored this larger evolution in PepGen Lab’s research coverage of single-, dual- and triple-receptor metabolic architectures.
CagriSema and zenagamtide take that story into another important branch:
GLP-1 + amylin.
The result is a research field increasingly defined not simply by individual compounds, but by molecular architecture.
2. CagriSema: Two Molecules, Two Signaling Systems
CagriSema is an investigational combination containing:
Cagrilintide — a long-acting amylin analogue
Semaglutide — a GLP-1 receptor agonist
This distinction matters.
CagriSema is not one newly engineered dual-receptor peptide.
It brings together two separate pharmacological components within one clinical research strategy.
Semaglutide represents the GLP-1 component.
Cagrilintide introduces amylin-receptor pharmacology.
That creates a relatively elegant experimental architecture:
GLP-1 signaling + amylin signaling
without requiring both receptor activities to be encoded into a single molecule.
By 2026, this architecture had accumulated substantial Phase 3 research.
The pivotal REDEFINE 1 trial enrolled 3,417 participants. In the published study, the estimated mean body-weight change at week 68 was −20.4% in the cagrilintide-semaglutide group compared with −3.0% with placebo under the trial’s treatment-policy estimand. Gastrointestinal adverse events were substantially more common in the combination group and were reported as predominantly transient and mild-to-moderate.
Those are results from a defined clinical trial involving an investigational pharmaceutical combination.
They are not results that can be transferred to unrelated research peptides or PepGen Lab products.
But from a research perspective, the study provides something extremely valuable:
large-scale evidence with which scientists can examine what happens when two complementary metabolic receptor systems are investigated together.
The contrast between CagriSema and zenagamtide illustrates how related signaling targets can be approached through fundamentally different molecular architectures.
3. Why Amylin Has Become Such an Important Research Target
GLP-1 has dominated public attention.
Amylin has received considerably less.
Scientifically, however, amylin represents a separate peptide-hormone system with its own receptor biology.
Amylin is normally co-secreted with insulin from pancreatic beta cells and participates in the integrated physiological response to nutrient intake.
Its signaling therefore provides researchers with a pathway that is related to—but mechanistically distinct from—GLP-1 receptor signaling.
That makes the combination scientifically interesting.
Instead of simply increasing activity at one receptor, researchers can investigate whether complementary biological signals create a different pharmacological profile when studied together.
This is the larger principle behind much of modern multi-pathway metabolic research.
For this reason, CagriSema and zenagamtide provide useful models for comparing combination pharmacology with unimolecular peptide engineering.
It is also why CagriSema is more interesting scientifically than simply calling it another GLP-1 program.
4. Zenagamtide: One Molecule, Two Receptor Systems
The compound many researchers first encountered under the name amycretin now has a new name:
Zenagamtide.
Zenagamtide is being developed as a unimolecular peptide agonist of GLP-1 and amylin receptors.
The word unimolecular is what separates its architecture from CagriSema.
CagriSema:
Cagrilintide + Semaglutide
Two pharmacological components
Zenagamtide:
One engineered peptide → GLP-1 receptor + amylin receptor
One molecular entity
That is a fundamentally different research strategy.
Rather than administering two complementary molecules together, researchers are investigating whether the desired receptor activities can be engineered into one molecular platform.
CagriSema and zenagamtide therefore reach toward related receptor biology through two distinctly different engineering strategies.
This is where contemporary peptide science becomes especially interesting.
The challenge is no longer merely discovering a peptide that interacts with a receptor.
Researchers can increasingly investigate how receptor activity, molecular stability, pharmacokinetics and pathway balance can be designed into the architecture of the molecule itself.
Amycretin Became Zenagamtide — But Both Names Matter
For anyone researching this field in 2026, the terminology deserves clarification.
Much of the earlier literature, news coverage and online search activity uses:
Amycretin
The current development name is:
Zenagamtide
For that reason, researchers searching either term are effectively following the same investigational program.
This is also why both names matter for scientific search visibility.
A modern research article discussing only “amycretin” risks becoming outdated.
An article discussing only “zenagamtide” may miss researchers still searching the compound under its earlier name.
The accurate terminology is therefore:
Zenagamtide (formerly amycretin).
What the Phase 2 Zenagamtide Research Found
Zenagamtide remains earlier in development than CagriSema, but its clinical program has advanced substantially.
In June 2026, a randomized, double-blind, placebo-controlled Phase 2 study evaluated once-weekly subcutaneous zenagamtide in adults with type 2 diabetes.
At week 36, the highest investigated dose was associated with a reported 14.6% mean body-weight reduction, alongside changes in HbA1c and other predefined study endpoints.
The program subsequently advanced toward Phase 3 development.
Again, these numbers should be interpreted correctly.
They describe observations within specific clinical trials involving zenagamtide.
They do not establish comparable effects for other peptides, metabolic research compounds, supplements or multi-compound matrices.
As their clinical programs develop, CagriSema and zenagamtide are providing researchers with increasingly detailed evidence for evaluating these contrasting approaches.
5. CagriSema and Zenagamtide: Why the Architecture Matters
| Research Feature | CagriSema | Zenagamtide / Amycretin |
|---|---|---|
| Molecular strategy | Combination pharmacology | Unimolecular engineering |
| GLP-1 pathway | Semaglutide | Incorporated into one molecule |
| Amylin pathway | Cagrilintide | Incorporated into one molecule |
| Pharmacological components | Two | One |
| Central research concept | Combine complementary agents | Engineer complementary receptor activity |
| Clinical-development stage | Phase 3 evidence | Phase 2 evidence / Phase 3 development |
| Status | Investigational | Investigational |
The important scientific question is therefore not simply:
Which compound produces the larger number?
A more interesting question is:
Which architecture offers the most effective way to coordinate multiple metabolic signals?
Comparing CagriSema and zenagamtide is ultimately less about ranking two programs and more about understanding the architecture behind each one.
That question extends far beyond these two investigational programs.
It reaches directly into the future of peptide engineering.
6. From Dual Pathways to Triple Agonists
GLP-1 + amylin is only one branch of this rapidly expanding field.
Other development programs are investigating architectures involving:
GLP-1 + GIP
GLP-1 + glucagon
GLP-1 + GIP + glucagon
and emerging combinations incorporating amylin into additional multi-receptor systems.
The larger direction is becoming clear.
Metabolic peptide research is moving from:
single receptor → dual receptor → multi-receptor
and from:
multiple compounds → increasingly sophisticated single-molecule designs
Viewed within this wider landscape, CagriSema and zenagamtide represent one important branch of the broader transition toward multi-pathway metabolic research.
This is not simply a race to add more targets.
Successful multi-receptor design requires researchers to understand how individual pathways interact and whether combining them produces a scientifically useful pharmacological profile.
More pathways do not automatically mean a better compound.
Architecture matters.
Where PepGen Lab Enters the Research Conversation
This evolution toward multi-pathway metabolic science is closely aligned with one of the core research categories being developed across the PepGen Lab RUO platform.
PepGen Lab’s metabolic research portfolio gives laboratories access to distinct research compounds representing different experimental pathways, allowing researchers to investigate individual mechanisms as well as more complex multi-compound architectures.
For example, PepGen Lab supplies AOD-9604 as analytical-grade lyophilized research material for laboratory investigation of the C-terminal hGH fragment 177–191 and associated metabolic-signaling questions.
The material is positioned strictly for laboratory research.
Researchers can also explore PepGen Lab’s educational material covering peptide science, research pathways and emerging molecular architectures.
The scientific evolution represented by CagriSema and zenagamtide is relevant to this wider research environment because laboratories increasingly examine not only individual compounds but also the relationships between different signaling pathways.
The PepGen Difference
For sophisticated pathway research, the identity of the compound is only part of the equation.
Purity, identity verification, analytical documentation and batch consistency matter.
That is why PepGen Lab’s research platform is built around analytically characterized materials and transparent research documentation rather than simply presenting a catalog of molecule names.
Researchers investigating metabolic signaling can explore PepGen Lab research materials relevant to their experimental models while maintaining a clear distinction between laboratory research compounds and approved or investigational medicines.
CagriSema and zenagamtide are not PepGen Lab products, and PepGen research materials are not represented as substitutes, equivalents or versions of those pharmaceutical candidates.
The connection is scientific:
the growing importance of multi-pathway research architecture.
7. Why CagriSema and Zenagamtide Matter for Future Research
For years, peptide research was often discussed molecule by molecule:
BPC-157
GHK-Cu
AOD-9604
Tesamorelin
MOTS-c
That remains important because every compound has its own molecular characteristics, experimental pathway, evidence base and research limitations.
But the frontier is moving toward another question:
How do pathways interact?
That changes how researchers think about experimental design.
Instead of investigating only one molecular signal, laboratories can increasingly examine:
pathway complementarity
receptor cross-talk
signal duration
molecular stability
pharmacokinetic differences
single-molecule versus multi-compound architecture
and
how multiple biological systems behave within the same experimental model.
That is precisely why CagriSema and zenagamtide deserve attention even from researchers who are not directly working with either pharmaceutical candidate.
They demonstrate where the broader field is moving.
The Commercial Evolution of Peptide Science
The extraordinary attention surrounding GLP-1 research has done something larger than create interest in one receptor family.
It has accelerated investment across peptide engineering, oral-delivery research, long-acting molecular design and multi-receptor pharmacology.
For research suppliers, laboratories and biotechnology developers, this creates an increasingly sophisticated market.
Researchers are no longer satisfied simply knowing that a compound has a recognizable peptide name.
The modern research environment increasingly demands:
defined molecular identity
verified purity
analytical documentation
clear research classification
and
a scientifically coherent reason for selecting one experimental pathway over another.
The development of CagriSema and zenagamtide reflects that wider movement toward increasingly sophisticated molecular design and more deliberate pathway selection.
This is where PepGen Lab intends to position itself:
not simply as another peptide catalog, but as a premium platform for the next generation of research compounds and multi-pathway laboratory investigation.
As the science becomes more sophisticated, the standard expected from research materials should rise with it.
What the Evidence Actually Shows
The evidence surrounding CagriSema and zenagamtide also demonstrates why development stage and study design must remain central to scientific interpretation.
CagriSema — Evidence Grade: Phase 3 Clinical Research
CagriSema has substantial randomized Phase 3 evidence.
REDEFINE 1 included 3,417 randomized participants, while additional Phase 3 studies have investigated the combination in other populations and research settings.
REIMAGINE 2 was published in 2026 and investigated CagriSema against its individual components in adults with type 2 diabetes and overweight or obesity.
Zenagamtide — Evidence Grade: Phase 2 / Advancing Clinical Development
Zenagamtide has completed important Phase 2 research and is progressing into Phase 3 development.
It remains an investigational compound.
The different development stages of CagriSema and zenagamtide are therefore important when comparing the quantity and maturity of available clinical evidence.
PepGen Research Materials — Research Use Only
No clinical results from CagriSema, semaglutide, cagrilintide or zenagamtide should be extrapolated to PepGen Lab research compounds.
PepGen products referenced in this article are presented exclusively in connection with laboratory metabolic-pathway research.
They are not represented as treatments, medicines, substitutes for pharmaceutical products or products intended to reproduce clinical-trial outcomes.
CagriSema and Zenagamtide Show Why the Next Generation Is About Architecture
CagriSema and zenagamtide reveal something much larger than the development of two investigational metabolic programs.
They demonstrate the changing logic of peptide science.
CagriSema asks what happens when two complementary pharmacological components are combined.
Zenagamtide asks whether those complementary receptor activities can instead be engineered into one peptide molecule.
Triple agonists push the concept even further.
Together, CagriSema and zenagamtide show how modern peptide research is increasingly being defined by pathway coordination rather than receptor activity alone.
The result is a rapidly evolving research landscape in which the defining question may no longer be:
“Which peptide are you studying?”
but:
“Which biological architecture are you investigating?”
The comparison between CagriSema and zenagamtide therefore provides a useful model for understanding where metabolic peptide science may be heading: away from isolated receptor targets and toward increasingly deliberate multi-pathway molecular design.
For PepGen Lab, that transition fits directly with the future we are building toward: high-purity research compounds, documented analytical quality and increasingly sophisticated pathway-focused research systems designed for the modern laboratory.
Scientific References & Verification
REDEFINE 1 — Cagrilintide + Semaglutide
The pivotal randomized Phase 3 study included 3,417 participants and provides peer-reviewed evidence for the CagriSema research program.
REIMAGINE 2 — CagriSema in Type 2 Diabetes
A randomized, double-blind Phase 3 study comparing the fixed combination with its individual components.
Page Disclaimer
The information provided in this section is intended strictly for informational and research purposes only. Our articles discuss published studies, emerging scientific developments, and general laboratory topics related to research compounds. References to approved or investigational medicines are included solely to discuss developments in peptide science and drug-delivery research and do not imply that PepGen Lab products are equivalent to, approved as, or intended to be used as those medicines. PepGen Lab research compounds are intended strictly for laboratory research and in-vitro testing. Not for human or animal consumption.
Author: PepGen Lab Research Team